Journals / Türk Kardiyoloji Derneği Arşivi / 2017 / Cilt: 45 - Sayı: Suppl. 5

What is aging and cardiovascular aging?

Yaşlılık ve kardiyovasküler yaşlanma nedir?

Pages
1–4
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

To understand these changes is important for targeting new preventive and therapeutic strategies such as control endothelial dysfunction, mitocondrial oxidative stress, chromatin remodeling, genomic instability and vascular repair modalities including bone marrow-derived sterm cell transplantation in the aging population.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aging is one of the main risk factors for cardiovascular disease (CVD) and results in a progressive functional decline of organs and the vasculature.
📊
Key Findings & Data:According to WHO data today, 8.5 percent of people worldwide (617 million) are aged 65 and over, this percentage is projected to jump to nearly 17 percent of the world’s population by 2050 (1.6 billion).
💡
Conclusion & Impact:To understand these changes is important for targeting new preventive and therapeutic strategies such as control endothelial dysfunction, mitocondrial oxidative stress, chromatin remodeling, genomic instability and vascular repair modalities including bone marrow-derived sterm cell transplantation in the aging population.
🔬Design:Modeling & Simulation
📍Scope:2050 Verileri
⚙️Variables:Domain Parameters

Abstract

Aging is one of the main risk factors for cardiovascular disease (CVD) and results in a progressive functional decline of organs and the vasculature. According to WHO data today, 8.5 percent of people worldwide (617 million) are aged 65 and over, this percentage is projected to jump to nearly 17 percent of the world’s population by 2050 (1.6 billion). Turkey’s 65-and- over population rise over the last 5 years about 17,1% and it is estimated that the percentage of this elderly population will rise from 8.5% (2016 data) to 20,8% in the year 2050. With aging the LV dynamics changes, afterload and myocardial oxygen consumption increase coronary perfusion decrease and the aorta stiffens due to increased collagen and reduced elastine level leading to a high systolic and low diastolic blood pressure and increased pulse wave velocity. At the cellular and mitochondrial level endothelial and vascular smooth muscle cells ‘(VSMC) have key structural and functional alterations that promote cardiovascular disease (CVD) and is defined as cardiovascular aging. To understand these changes is important for targeting new preventive and therapeutic strategies such as control endothelial dysfunction, mitocondrial oxidative stress, chromatin remodeling, genomic instability and vascular repair modalities including bone marrow-derived sterm cell transplantation in the aging population.

Özet

Yaşlılık kardiyovasküler hastalıklar için en önemli risk faktörlerinden biri olup organların ve damar sisteminin ilerleyici fonksiyon kaybı ile karakterizedir. Dünya Sağlık Örgütü (WHO) 65 yaş ve üzeri kişileri yaşlı olarak tanımlamaktadır. Yaşlılar Dünya nüfusunun %8.5'ini (617 milyon) oluşturmaktadır, bu oranın 2050 yılında %17'ye sıçrayacağı ve yaşlı kişi sayısının 1.6 milyara ulaşacağı öngörülmektedir. Türkiye İstatistik Kurumu (TÜİK) verilerine göre ülkemizde 65 yaş üstü nüfus son beş yılda %17.1 artarak 2016 yılında toplam nüfus içindeki oranı %8.3'e yükselmiş ve 6 milyon 651 bin 503 kişiye ulaşmıştır. 2050 yılında bu oranın %20.8'e ulaşacağı öngörülmektedir. Kardiyovasküler yaşlanma denince sol ventrikül dinamiğinde, aortanın elastikiyetinde, mitokondriyal ve hücresel düzeyde ise endotel ve damar düz kas hücrelerinde meydana gelen yapısal ve fonksiyonel değişimler anlaşılır. Bunların bilinmesi yaşlanan popülasyon için gelecekte endoteliyal disfonksiyon ve mitokondriyal oksitatif stres yanısıra kromatin remodeling ve genomik instabilitenin düzenlenmesi ayrıca vasküler onarımı desteklemek için otolog kemik iliği kökenli kök hücre transplantasyonu gibi yeni koruyucu ve tedavi edici seçeneklerinin gelişmesi açısından önemlidir.

🔖

Cite This Article

KOLDAŞ, Z. L. (2022). What is aging and cardiovascular aging?. Türk Kardiyoloji Derneği Arşivi, Cilt: 45 - Sayı: Suppl. 5, 1–4. https://ajindex.com/articles/632292

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Paneni F, Diaz Cañestro C, Libby P, Lüscher TF, Camici GG. The Aging Cardiovascular System: Understanding It at the Cellular and Clinical Levels. J Am Coll Cardiol 2017;69:1952–67
  2. North BJ, Sinclair DA. The intersection between aging and cardiovascular disease. Circ Res 2012;110:1097–108
  3. Beğer T, Yavuzer H. Yaşlılık ve Yaşlılık Epidemiyolojisi. Klinik Gelişim 2012;25:1–3
  4. He W, Goodkind D, Kowal P. An Aging World: 2015 Census Bureau. Available at: https://www.census.gov/content/dam/Census/library/publications/2016/./ p95-16-1.pdf. Accessed Aug 7, 2017
  5. TÜİK. İstatistiklerle Yaşlılar 2016. TÜİK Haber Bülteni 2017:24644
  6. Camici GG, Savarese G, Akhmedov A, Lüscher TF. Molecular mechanism of endothelial and vascular aging: implications for cardiovascular disease. Eur Heart J 2015;36:3392–403
  7. Afilalo J, Karunananthan S, Eisenberg MJ, Alexander KP, Bergman H. Role of frailty in patients with cardiovascular disease. Am J Cardiol 2009;103:1616–21
  8. Taddei S, Virdis A, Ghiadoni L, Salvetti G, Bernini G, Magagna A, et al. Agerelated reduction of NO availability and oxidative stress in humans. Hypertension 2001;38:274–9
  9. Donato AJ, Gano LB, Eskurza I, Silver AE, Gates PE, Jablonski K, et al. Vascular endothelial dysfunction with aging: endothelin-1 and endothelial nitric oxide synthase. Am J Physiol Heart Circ Physiol 2009;297:H425–32
  10. Rapola JM, Virtamo J, Ripatti S, Huttunen JK, Albanes D, Taylor PR, et al. Randomised trial of alpha-tocopherol and beta-carotene supplements on incidence of major coronary events in men with previous myocardial infarction. Lancet 1997;349:1715–20
  11. Jarski RW, Hightower KR, Dangovian MI. Vitamin E supplementation, cardiovascular events, and cancer. JAMA 2005;294:425–6
  12. Venkatasubramanian S, Noh RM, Daga S, Langrish JP, Joshi NV, Mills NL, et al. Cardiovascular effects of a novel SIRT1 activator, SRT2104, in otherwise healthy cigarette smokers. J Am Heart Assoc 2013;2:e000042
  13. Winnik S, Auwerx J, Sinclair DA, Matter CM. Protective effects of sirtuins in cardiovascular diseases: from bench to bedside. Eur Heart J 2015;36:3404–12
  14. Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y, et al. Stressdependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 2004;303:2011–5
  15. Ungvari Z, Parrado-Fernandez C, Csiszar A, de Cabo R. Mechanisms underlying caloric restriction and lifespan regulation: implications for vascular aging. Circ Res 2008;102:519–28